Dendrite Clinical Support Business Gains Global Momentum
Dendrite International, Inc. (NASDAQ: DRTE) has announced continued expansion of its global clinical trial services business.
(PRWEB) February 9, 2003
Dendrite International, Inc. (NASDAQ: DRTE) has announced continued expansion of its global clinical trial services business. Working in partnership with the Japanese subsidiary of a major pharmaceutical company, Dendrite has begun providing support services for another new clinical trial commencing in Japan, having successfully completed work for this client during two previous clinical trials.
Dendrite will again provide data entry services, study analysis services and completion of study reports. Dendrite also conducts work in Japan for its largest global EDC (electronic data capture) client, including testing and validating all computer hardware for clinical investigators and providing complete on-site and web-based training for clinical site personnel. In addition, Dendrite provides 24x7, multilingual help desk support for staff at investigative sites..
“Every delay in a clinical trial can cost the sponsoring pharmaceutical company millions in potential lost revenue,” said Kiyoteru Takenouchi, Dendrite Japan Director, Clinical Services Division. “Therefore, drug manufacturers have a vested interest in assuring that their clinical trials are conducted safely and quickly and that their new products quickly reach the market to improve patient health and well-being. A key part of this process, and where Dendrite plays an important role, is in the proper collection and management of data.”
A full version of this news release is available at:
Http://www. dendrite. com/news/press/pr2003/020503.htm (http://www. dendrite. com/news/press/pr2003/020503.htm).
THIS RELEASE HAS BEEN DISTRIBUTED BY WEBITPR (www. webitpr. com)
Disclaimer:
Whilst WebitPR. com Limited endeavor to ensure the accuracy of the information contained in this Release, WebitPR. com Limited cannot accept any liability for:-
• the inaccuracy or otherwise of any information contained in this Release; or
• any loss liability or expense which may be suffered by any party in consequence of acting or omitting to act as a result of any information contained in or omitted from this Release.; or
• any loss or suffering which may be caused by or to any party either as a result of the information contained in this Release or such information contained in this Release being inaccurate or otherwise misleading.
In the event that any information contained in this Release is inaccurate or misleading then please contact WebitPR. com at the above e-mail address.
